Ladenburg Thalmann Maintains Buy on NovaBay Pharmaceuticals, Lowers Price Target to $3.8
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann has maintained its 'Buy' rating on NovaBay Pharmaceuticals (AMEX:NBY) but has lowered the price target from $6 to $3.8.
August 11, 2023 | 3:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
NovaBay Pharmaceuticals' price target has been lowered by Ladenburg Thalmann from $6 to $3.8, though the 'Buy' rating is maintained.
The news directly pertains to NovaBay Pharmaceuticals. While the 'Buy' rating is maintained, the lowered price target may indicate a potential slowdown in growth or increased risk, which could impact investor sentiment and the stock's short-term price. However, the impact is not necessarily negative as the 'Buy' rating is still in place.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100